Nathan Pennell, MD, PhD of Cleveland Clinic discusses what’s next for his study on maintenance pembrolizumab for patients with small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 8504: Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)
Advertisement